Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients

BACKGROUND: Saquinavir/ritonavir (1000/100 mg twice daily [BID]) is associated with dose- and exposure-dependent prolongation of the QT interval. The QT risk is considered higher during the first week of therapy, when saquinavir peak exposure has been observed. A modified regimen with a lower dose l...

Descripción completa

Detalles Bibliográficos
Autores principales: Boffito, Marta, Jackson, Akil, Pozniak, Anton, Giraudon, Mylene, Kulkarni, Rohit, Abelardo, Maria Connie, Patel, Indravadan H., Morcos, Peter N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359187/
https://www.ncbi.nlm.nih.gov/pubmed/25742730
http://dx.doi.org/10.1007/s40268-015-0087-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359187/
https://www.ncbi.nlm.nih.gov/pubmed/25742730
http://dx.doi.org/10.1007/s40268-015-0087-7

Ejemplares similares